News | July 01, 2022
H Clinical adds commercial home health capabilities for pharma industry
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
First and only PARP inhibitor to improve invasive disease-free survival in patients
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Silo enters into commercial evaluation license agreement for next generation liposomes
Subscribe To Our Newsletter & Stay Updated
